BIOMARIN PHAR. DL-,001 | 68.65 / +2.36% |
Date/Time | 01/18 / 08:08 |
Chg. / Chg.(%) | 1.58 / +2.36% |
Bid | 68.52 / 100 |
Ask | 68.83 / 100 |
Open | 68.65 |
Previous Close | 67.07 |
High | 68.65 |
Low | 68.65 |
Volume [EUR] | 2,059.50 |
Volume [Units] | 30 |
Price fixings | 1 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | München |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
TradeGate | 68.870 | ![]() |
92 |
Frankfurt | 68.5400 | ![]() |
45 |
München | 68.65 | ![]() |
30 |
Berlin | 68.40 | ![]() |
0 |
Düsseldorf | 68.58 | ![]() |
0 |
Vienna Globa.. | 68.46 | ![]() |
0 |
Lang & Schwa.. | 68.58 | ![]() |
|
Stuttgart | 68.550 | ![]() |
|
gettex | 68.680 | ![]() |
|
NASDAQ | 82.9700 | ![]() |
1,306,558 |
Cboe US | 82.85 | ![]() |
89,343 |
IEX | 82.89 | ![]() |
62,135 |
Xetra | 68.08 | 0 | |
Mexico | 1,599.31 | ![]() |
4,200 |
London Inter.. | 81.84 | 295 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire